0001652935 1 2026-10-18 2026-10-18 0001652935 2 2026-10-18 2026-10-18 0001652935 3 2026-10-18 2026-10-18 0001652935 4 2026-10-18 2026-10-18 0001652935 5 2026-10-18 2026-10-18 0001652935 6 2026-10-18 2026-10-18 0001652935 7 2026-10-18 2026-10-18 0001652935 1 2026-10-18 2026-10-18 0001652935 2 2026-10-18 2026-10-18 0001652935 2026-10-18 2026-10-18 iso4217:USD pure S-1/A EX-FILING FEES 0001652935 333-299332 true false N/A S-1 ACTUATE THERAPEUTICS, INC. true Equity Common Stock true 17250000.00 1500.75 true Equity Purchase Warrants true 0.00 true Equity Warrants to be issued to the underwriter(c) true 0.00 true Equity Pre-Funded Warrants true 0.00 false Equity Common stock underlying Purchase Warrants true 17250000.00 0.000087 1500.75 true Equity Common stock underlying warrants to be issued to the underwriter true 754688.00 65.66 true Equity Common stock underlying Pre-Funded Warrants true 0.00 35254688.00 3067.16 0.00 2375.73 691.43 In accordance with Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall be deemed to cover an indeterminate number of additional shares of common stock to be offered or issued from stock splits, stock dividends or similar transactions. The proposed maximum aggregate offering price has been estimated solely to calculate the registration fee in accordance with Rule 457(o) under the Securities Act. We have agreed to issue to the representative of the underwriters warrants to purchase shares of common stock representing up to 3.5% of the common stock issued in the offering (including the pre-funded warrants issued in the offering). The representative’s warrants are exercisable at a per share exercise price equal to 125% of the public offering price per share of the common stock offered hereby. No separate registration fee required pursuant to Rule 457(g). The registrant may issue pre-funded warrants to purchase shares of common stock in the offering. The purchase price of each pre-funded warrant will equal the price per share at which shares of common shares are being sold to the public in this offering, minus $0.0001, which constitutes the pre-funded portion of the exercise price, and the remaining unpaid exercise price of the pre-funded warrant will equal $0.0001 per share (subject to adjustment as provided for therein). The proposed maximum aggregate offering price of the common stock will be reduced on a dollar-for-dollar basis based on the offering price of any pre-funded warrants issued in the offering, and the proposed maximum aggregate offering price of the pre-funded warrants to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any common stock issued in the offering. Accordingly, the proposed maximum aggregate offering price of the common stock and pre-funded warrants (including the common stock issuable upon exercise of the pre-funded warrants), if any, is $17,250,000. true S-1 333-299332 2026-10-06 2375.73 true Actuate Therapeutics, Inc. S-1 333-299332 2026-10-06 2375.73 The Company previously paid $2,375.73 with respect to common stock included herein based on a maximum aggregate offering price of $34,500,000.00 in connection with its filing of the Registration Statement on Form S-1 (File No. 333-299332) on October 6, 2026. In accordance with Rule 457(b) under the Securities Act, the Company is using $2,375.73 of the previously paid fees to offset the filing fee payable in connection with this Registration Statement.